• -->


The AC Forum Lunch & Learn Webinar Series covers important and timely topics in anticoagulation care. The webinars are presented each month by international experts, and moderated by a multidisciplinary team of AC Forum board members. Each one hour webinar is presented free of charge and is open to all healthcare professionals. All webinars require pre-registration.

Register for Upcoming Webinars

December Webinar: Evidence-Based Best Practices for Outpatient Management of Warfarin
Wednesday, December 5, 2018 12:00 PM ET

Guest Author:
Adam Rose, MD, MSc, FRCPC

Many best practices have been described for organizing a clinic to manage warfarin. Although these practices may have face validity, they may not be based on empirical analysis. Here, we describe our decade-long effort to apply the Structure-Process-Outcome model of quality measurement as a basis for measuring and improving outpatient warfarin management in the Veterans Health Administration. The purpose of the article is to raise awareness of this body of work with pharmacists who could potentially incorporate the findings of this work into their own practice settings. We conclude with concrete suggestions for immediate implementation in clinical settings.

Adam Rose is a physician policy researcher at the RAND Corporation, focusing on improving prescribing and measuring quality of care. From 2008-2016, he served as an investigator at the VA Center for Healthcare Organization and Implementation Research, and from 2013-2016 he led their Medication Optimization Program, one of three topical foci for the center. His largest research effort, spanning almost a decade, has been focused on improving the management of oral anticoagulants. The performance measures developed by Dr. Rose and his colleagues for anticoagulation are now used across the entire VA system. Dr. Rose received his M.D. from the University of Pennsylvania.

Webinar Archive

All webinars are recorded and can be viewed below.

Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated VTE: Guidance from the SSC of the ISTH
November 6, 2018
Dr. Marc Carrier, MD, MSc, FRCPC
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD
October 11, 2018
Geoff Barnes, MD; Scott Damrauer, MD
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
July 18, 2018
Suresh Vedantham, MD
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
June 6, 2018
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
May 9, 2018
Adam Cuker, MD
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
March 28, 2018
John Fanikos, RPh, MBA; Paul Dobesh, PharmD, FCCP, BCPS; Curt Mahan, PharmD
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS Trail)
February 8, 2018
John Eikelboom, MB, BS
HOKUSAI VTE Cancer Trial: Edoxaban for the Treatment of Cancer-Associated VTE
January 9, 2018
David Garcia, MD
Using Clinical Order Sets to Integrate Quality Standards into Point of Care
December 15, 2017
Scott Kaatz, DO, MSc, FACP, SFHM; Geoff Barnes, MD, MSc; Eva Kline-Rogers, MS, NP, AACP; Stacy Ellsworth, RN, MSN, CCRC
A Multifaceted Intervention to Improve Treatment with Oral Anticoagulants in Atrial Fibrillation (IMPACT-AF): An International, Cluster-Randomised Trial
November 15, 2017
Renato D. Lopes, MD, MHS, PhD
Re-Circuit Trial
October 17, 2017
Edward Gerstenfeld, MD
Extended Thrombo-prophylaxis with Betrixaban in Acutely Ill Medical Patients
August 16, 2017
C. Michael Gibson, MD
Prevention of Thromboembolic Complications in Patients with Superficial-Vein Thrombosis Given Rivaroxaban or Fondaparinux
June 20, 2017
Jan Beyer-Westendorf, MD
Einstein Choice Trial
May 23, 2017
Jeff Weitz, MD, PhD
Ticagrelor vs. Clopidogrel in Symptomatic Peripheral Artery Disease
March 28, 2017
William Hiatt, MD
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
February 28, 2017
C. Michael Gibson, MD
Anticoagulant Therapy for Symptomatic Calf DVT (CACTUS)
January 11, 2017
Marc Carrier, MD, MSc; Gregoire Le Gal, MD, PhD
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
December 15, 2016
Peter A. Noseworthy, MD; Xiaoxi Yao, PhD, MPH, MS
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
October 25, 2016
Jean M. Connors, MD; Megan E. Barra, PharmD; John Fanikos, RPh, MBA
Reducing the Hospital Burden of HIT: Impact of an Avoid-Heparin Program
September 29, 2016
William Geerts, MD
Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of VTE
August 17, 2016
Maureen Smythe, PharmD; Paul Dobesh, PharmD; Diane Wirth, ANP; Adam Cuker, MD and Jack Ansell, MD
NATF Atrial Fibrillation Consensus Document
June 30, 2016
Christian T. Ruff, MD, MPH
Effect of Body Weight on the Efficacy and Safety of the DOACs in VTE
May 12, 2016
Francesco Dentali, MD
Guidance for the Evaluation and Treatment of Hereditary and Acquired Thrombophilia
March 30, 2016
Scott Stevens, MD
Guidance for the Prevention and Treatment of Cancer-Associated VTE
March 3, 2016
David Garcia, MD; Jack Ansell, MD
Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment
February 9, 2016
Allison Burnett, PharmD; Sara Vazquez, PharmD; Jack Ansell, MD
Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
January 20, 2016
Jack Ansell, MD; Michael Streiff, MD; Mark Crowther, MD
The Changing Characteristics of Atrial Fibrillation Patients Treated with Warfarin
December 1, 2015
Eva Kline-Rogers, NP; Geoff Barnes, MD; Scott Kaatz, DO
Clinical Monitoring of DOACs: "Site-Level Variation in and Practices Associated with Dabigatran Adherence"
October 20, 2015
Supriya Shore, MD
Idarucizumab for Dabigatran Reversal
September 30, 2015
Charles Pollack, Jr., MD; Jeffrey Weitz, MD
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
August 25, 2015
James Douketis, MD; David Garcia, MD; Scott Kaatz, DO
Clinical Characteristics & Outcomes with Rivaroxaban vs. Warfarin in Patients with NVAF but Underlying Native Mitral and Aortic Valve Disease Participating in the ROCKET AF Trial
June 16, 2015
Richard C. Becker, MD
Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial
May 14, 2015
Christopher Granger, MD; Renato Lopes, MD, PhD
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation
March 17, 2015
Benjamin Steinberg, MD; Jack Ansell, MD
An Evaluation of the Potential Drug Interaction Between Warfarin and Levothyroxine
February 19, 2015
John R. Horn, PharmD; Michele D. Wood, PharmD; Nathan Clark, PharmD; Daniel M. Witt, PharmD
Edoxaban vs Warfarin in Patients with Atrial Fibrillation
January 20, 2015
Robert Giugliano, MD; Christian Ruff, MD, MPH
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
November 20, 2014
Jeffrey S. Dlott, MD
Patient Webinar - DVT and PE Discussion in Honor of World Thrombosis Day
October 16, 2014
Stephan Moll, MD
Antibiotic Interaction with Warfarin in the Ambulatory Setting
September 18, 2014
Nathan Clark, PharmD; Adam Cuker, MD; Scott Kaatz, DO, MSc
A Review of RE-COVER I and II: FDA Approves use of Dabigatran for treatment of acute VTE
June 19, 2014
Samuel Z. Goldhaber, MD; Adam Cuker, MD; Scott Kaatz, DO, MSc
Compression Stockings to Prevent Post-thrombotic Syndrome: A Randomized Placebo-controlled Trial
May 15, 2014
Susan R. Kahn, MD, MSc
Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic
April 16, 2014
Jenny Lopez, MD, MPH, MDiv; Lynn B. Oertel, MS, ANP; Scott Kaatz, DO, MSc
Anticoagulation Centers of Excellence: A Case-Based Demonstration
March 20, 2014
Daniel M. Witt, PharmD, FCCP, BCPS, CACP; Arthur Allen, PharmD, CACP; Allison Burnett, PharmD, PhC, CACP; Elaine Whalen, MBA
CLOTS3 Trial: AC Forum and Thrombosis Canada
September 19, 2013
Professor Martin Dennis
FDA Postmarketing Report on Dabigatran
July 18, 2013
Mary Ross Southworth, PharmD; Marsha E. Reichman, PhD; Ellis F. Unger, MD